Navigation Links
Sigma-Tau Pharmaceuticals, Inc. Announces Addition of VP of Finance
Date:7/1/2011

GAITHERSBURG, Md., July 1, 2011 /PRNewswire/ -- Sigma-Tau Pharmaceuticals, Inc. announced the appointment of Dave Lemus as its new vice president of finance, effective July 1, 2011.  Lemus will join the leadership team at Sigma-Tau Pharmaceuticals U.S. corporate headquarters in Gaithersburg, Md.

For the past 13 years, Lemus served as chief financial officer of MorphoSys AG (FSE: MOR; Prime Standard Segment; TecDAX), one of the Europe's leading biotechnology companies focused on fully human antibodies.  In this position, he held responsibilities for a variety of areas, including corporate development, technical operations, corporate legal, human resources, and public and investor relations.  In 1999, Lemus led the effort to take the company public, successfully completing Germany's first-ever biotech initial public offering.  For the next decade thereafter, he played a central role in helping grow the company into one of Europe's leading life science companies.

"I'm very pleased to become part of the Sigma-Tau growth story going forward as its new vice president of finance," commented Lemus.  "Moreover, Sigma-Tau's considerable expertise in rare diseases will continue to play a decisive role in propelling the company's high rate of growth and expansion over the coming years."

Prior to his role at MorphoSys AG, Lemus was a controller and operations manager at Hoffmann-La Roche, and preceding this position, he served as the treasurer of the Lindt Chocolate Company.

"As a leader in the development and commercialization of medicines for rare diseases, we have undergone tremendous growth in the past few years," said Gregg Lapointe, CEO, Sigma-Tau Pharmaceuticals, Inc.  "In looking to the future, it's imperative we have talented people like Dave to help Sigma-Tau continue to bring innovation to the field of rare diseases.  We're very pleased to welcome him to the team."

Sigma-Tau Pharmaceuticals, Inc. is dedicated to creating novel medicines for the unmet needs of patients with rare diseases.  

About Sigma-Tau Pharmaceuticals, Inc.
Sigma-Tau Pharmaceuticals, Inc. is a U.S.-based, wholly owned subsidiary of the Sigma-Tau Group, and is dedicated solely to the global development and commercialization of medicines for patients with rare diseases.  Sigma-Tau Pharmaceuticals, Inc. is based in Gaithersburg, Md.  Since 1989, the company's products have been focused on rare diseases, including kidney disease, certain genetic disorders and cancers.  With more than 7,000 identified rare diseases that affect approximately 25 million patients in the United States, Sigma-Tau places its considerable scientific resources behind the development and commercialization of compounds that benefit the few.  The company has a substantial development program focused on transplant, cancer, inherited genetic disorders, malaria and other areas of unmet medical need.  For more information about the company, visit www.sigmatau.com.


'/>"/>
SOURCE Sigma-Tau Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. DOR BioPharma Announces Private Equity Financing of $3.85 Million with its Partner Sigma-Tau and Other Institutional Investors
2. Sigma-Tau Pharmaceuticals Announces Approval for New Manufacturing Process for ONCASPAR® (Pegaspargase) Primary Ingredient
3. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
4. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
5. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
6. Acura Pharmaceuticals, Inc. Secures Financing to Fund Pivotal Phase III Clinical Trial for Lead Aversion(R) Technology Product Candidate
7. Sucampo Pharmaceuticals, Inc. Begins Pivotal Phase III Studies of Oral Lubiprostone to Treat Opioid-Induced Bowel Dysfunction (OBD)
8. Symbollon Pharmaceuticals, Inc. Evaluates the Clinical Effects of IoGen(TM) on Fibrocystic Breast Disease
9. Aegerion Pharmaceuticals, Inc. Presents Final Results of Phase II Clinical Trials for AEGR-733 at Drugs Affecting Lipid Metabolism (DALM) 2007 Conference
10. Keryx Biopharmaceuticals, Inc. Announces Positive Preliminary Phase 2 Data on KRX-0401 in Patients with Chemo-Insensitive Rare Sarcoma
11. Quark Pharmaceuticals, Inc. Announces First Systemic siRNA Dosing in Humans
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/2/2017)... Oct. 2, 2017 Halo Labs announces the European launch ... called the HORIZON at MIBio 2017 in Cambridge, U.K ... visible particulate matter in biopharmaceutical samples with unprecedented speed and sensitivity ... novel technique Backgrounded Membrane Imaging. ... The HORIZON subvisible particle analysis system ...
(Date:9/28/2017)... -- Hill-Rom Holdings, Inc. (NYSE: HRC), will host its ... on Friday, November 3, 2017, beginning at 7:00 a.m. ... 8:30 a.m. (CDT) / 9:30 a.m. (EDT). ... and guidance for 2018, Hill-Rom executives will also highlight ... and long-range financial outlook through 2020. ...
(Date:9/27/2017)... MIAMI , Sept. 27, 2017  Commended for their ... recent notable awards. Ranked as number one in the South ... ninth time in Inc. 5000 yearly list, the national specialty ... CEO, Armando Bardisa will soon be honored by ... Set to receive his award ...
Breaking Medicine Technology:
(Date:10/13/2017)... ... October 13, 2017 , ... ... Software Development, has been awarded a contract by the Center for Medicare and ... aims to accelerate the enterprise use of Agile methodologies in a consistent and ...
(Date:10/13/2017)... ... 13, 2017 , ... “America On The Brink”: the Christian history of the ... is the creation of published author, William Nowers. Captain Nowers and his wife, ... he spent thirty years in the Navy. Following his career as a naval ...
(Date:10/12/2017)... ... October 12, 2017 , ... ... sleep apnea using cutting-edge Oventus O2Vent technology. As many as 18 ... characterized by frequent cessation in breathing. Oral appliances can offer significant relief to ...
(Date:10/12/2017)... ... October 12, 2017 , ... The company has developed ... consumer and regulatory authorities worldwide. From Children’s to Adults 50+, every formula has ... highest standard. , These products are also: Gluten Free, Non-GMO, Vegan, Soy ...
(Date:10/12/2017)... ... 12, 2017 , ... The American College of Medical Informatics (ACMI) will present ... the Opening Session of AMIA’s Annual Symposium in Washington, D.C. AMIA’s Annual Symposium ... Collen, a pioneer in the field of medical informatics, this prestigious award is presented ...
Breaking Medicine News(10 mins):